pharma · Metastatic castration-resistant prostate cancer. · short-term treatment of insomnia
Orion Laboratories Pty
Orion Laboratories Pty.
Orion Laboratories is a pharma organization headquartered in Baton Rouge, USA. Primary therapeutic focus areas include Metastatic castration-resistant prostate cancer., short-term treatment of insomnia, Parkinson desease
Company details
- Status
- Public
- HQ
- Baton Rouge, USA
- Founded
- 2008
- Employees
- 52
- Programs
- 9
- Drugs
- 20
- Patents
- 0
3124001
Phase 2 · small molecule · Metastatic castration-resistant prostate cancer.
3124001 for Metastatic castration-resistant prostate cancer. is a Phase 2 program (small_molecule) at Orion Laboratories Pty. with 1 ClinicalTrials.gov record(s).
Internal code 3124001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Orion Laboratories Pty.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metastatic castration-resistant prostate cancer.
- Status
- active
- Trials
- 1